A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...

Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for ...

Environmental activists yesterday voiced optimism that the threat of further oil exploration and drilling in this nation’s territorial waters has ceased after The Bahamas joined a pact to phase-out ...

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest ...

Picks this month include a Bob Dylan sleeper, a harrowing portrait of Syria, and Will Ferrell and Harper Steele’s road trip.

Eoptic Inc. has been awarded a $1.25 million Direct-to-Phase II Small Business Innovation Research (SBIR) contract by the U.S ...

Mayor LaToya Cantrell's administration and renter advocacy groups also say the program, dubbed Healthy Homes, has had success ...

Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, ...

Glenmark in an exchange filing said that the first clinical data from Phase 1 study of Trispecific TREAT Antibody ... Vincent's Hospital Melbourne was quoted as saying. T cell activation, ...

Ruxolitinib was approved based on the COMFORT trials. 6,7 COMFORT-I [NCT00952289] was a randomized phase 3 trial that ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...